

WHAT IS CLAIMED IS:

1. Isolated nucleic acid having at least 80% sequence identity to a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 9 (SEQ ID NO:14), Figure 12 (SEQ ID NO:20), Figure 15 (SEQ ID NO:23), Figure 18 (SEQ ID NO:28), Figure 20 (SEQ ID NO:30), Figure 23 (SEQ ID NO:33), Figure 25 (SEQ ID NO:36), Figure 27 (SEQ ID NO:41), Figure 30 (SEQ ID NO:47), Figure 32 (SEQ ID NO:52), Figure 34 (SEQ ID NO:57), Figure 36 (SEQ ID NO:62), Figure 38 (SEQ ID NO:67), Figure 41 (SEQ ID NO:73), Figure 47 (SEQ ID NO:84), Figure 49 (SEQ ID NO:95), Figure 51 (SEQ ID NO:97), Figure 53 (SEQ ID NO:99), Figure 57 (SEQ ID NO:103), Figure 64 (SEQ ID NO:113), Figure 66 (SEQ ID NO:115), Figure 68 (SEQ ID NO:117), Figure 70 (SEQ ID NO:119), Figure 72 (SEQ ID NO:124), Figure 74 (SEQ ID NO:129), Figure 76 (SEQ ID NO:135), Figure 79 (SEQ ID NO:138), Figure 83 (SEQ ID NO:146), Figure 85 (SEQ ID NO:148), Figure 88 (SEQ ID NO:151), Figure 90 (SEQ ID NO:153), Figure 93 (SEQ ID NO:156), Figure 95 (SEQ ID NO:158), Figure 97 (SEQ ID NO:160), Figure 99 (SEQ ID NO:165), Figure 101 (SEQ ID NO:167), Figure 103 (SEQ ID NO:169), Figure 105 (SEQ ID NO:171), Figure 109 (SEQ ID NO:175), Figure 111 (SEQ ID NO:177), Figure 113 (SEQ ID NO:179), Figure 115 (SEQ ID NO:181), Figure 117 (SEQ ID NO:183), Figure 120 (SEQ ID NO:189), Figure 122 (SEQ ID NO:194), Figure 125 (SEQ ID NO:197), Figure 127 (SEQ ID NO:199), Figure 129 (SEQ ID NO:201), Figure 131 (SEQ ID NO:203), Figure 133 (SEQ ID NO:205), Figure 135 (SEQ ID NO:207), Figure 137 (SEQ ID NO:209), Figure 139 (SEQ ID NO:211), Figure 141 (SEQ ID NO:213), Figure 144 (SEQ ID NO:216), Figure 147 (SEQ ID NO:219), Figure 149 (SEQ ID NO:221), Figure 151 (SEQ ID NO:223), Figure 153 (SEQ ID NO:225), Figure 155 (SEQ ID NO:227), Figure 157 (SEQ ID NO:229), Figure 159 (SEQ ID NO:231), Figure 161 (SEQ ID NO:236), Figure 163 (SEQ ID NO:241), Figure 165 (SEQ ID NO:246), Figure 167 (SEQ ID NO:248), Figure 169 (SEQ ID NO:250), Figure 171 (SEQ ID NO:253), Figure 174 (SEQ ID NO:256), Figure 176 (SEQ ID NO:258), Figure 178 (SEQ ID NO:260), Figure 180 (SEQ ID NO:262), Figure 182 (SEQ ID NO:264), Figure 184 (SEQ ID NO:266), Figure 186 (SEQ ID NO:268), Figure 188 (SEQ ID NO:270), Figure 190 (SEQ ID NO:272), Figure 192 (SEQ ID NO:274), Figure 194 (SEQ ID NO:276), Figure 196 (SEQ ID NO:278), Figure 198 (SEQ ID NO:281), Figure 200 (SEQ ID NO:283), Figure 202 (SEQ ID NO:285), Figure 204 (SEQ ID NO:287), Figure 206 (SEQ ID NO:289), Figure 208 (SEQ ID NO:291), Figure 210 (SEQ ID NO:293), Figure 212 (SEQ ID NO:295), Figure 214 (SEQ ID NO:297), Figure 216 (SEQ ID NO:299), Figure 218 (SEQ ID NO:301), Figure 220 (SEQ ID NO:303), Figure 226 (SEQ ID NO:309), Figure 228 (SEQ ID NO:314), Figure 230 (SEQ ID NO:319), Figure 233 (SEQ ID NO:326), Figure 235 (SEQ ID NO:334), Figure 238 (SEQ ID NO:340), Figure 240 (SEQ ID NO:345), Figure 242 (SEQ ID NO:347), Figure 244 (SEQ ID NO:349), Figure 246 (SEQ ID NO:351), Figure 248 (SEQ ID NO:353), Figure 250 (SEQ ID NO:355), Figure 252 (SEQ ID NO:357), Figure 254 (SEQ ID NO:359), Figure 256 (SEQ ID NO:361), Figure 258 (SEQ ID NO:363), Figure 260 (SEQ ID NO:365), Figure 262 (SEQ ID NO:367), Figure 264 (SEQ ID NO:369), Figure 266 (SEQ ID NO:371), Figure 268 (SEQ ID NO:373), Figure 270 (SEQ ID NO:375), Figure 272 (SEQ ID NO:377), Figure 274 (SEQ ID NO:379), Figure 276 (SEQ ID NO:381), Figure 278 (SEQ ID NO:387), Figure 280 (SEQ ID NO:389), Figure 282 (SEQ ID NO:394), Figure

284 (SEQ ID NO:399), Figure 286 (SEQ ID NO:401), Figure 288 (SEQ ID NO:403), Figure 290 (SEQ ID NO:408), Figure 292 (SEQ ID NO:410), Figure 294 (SEQ ID NO:412), Figure 296 (SEQ ID NO:414), Figure 298 (SEQ ID NO:416), Figure 300 (SEQ ID NO:418), Figure 302 (SEQ ID NO:420), Figure 304 (SEQ ID NO:422), Figure 306 (SEQ ID NO:424), Figure 308 (SEQ ID NO:495), Figure 310 (SEQ ID NO:497), Figure 312 (SEQ ID NO:499), Figure 314 (SEQ ID NO:501), Figure 316 (SEQ ID NO:503), Figure 318 (SEQ ID NO:505), Figure 320 (SEQ ID NO:507), Figure 322 (SEQ ID NO:509), Figure 324 (SEQ ID NO:511), Figure 326 (SEQ ID NO:513), Figure 328 (SEQ ID NO:515) and Figure 330 (SEQ ID NO:517).

2. The nucleic acid sequence of Claim 1, wherein said nucleotide sequence comprises a nucleotide sequence selected from the group consisting of the sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:5), Figure 5 (SEQ ID NO:7), Figure 8 (SEQ ID NO:13), Figure 11 (SEQ ID NO:19), Figure 14 (SEQ ID NO:22), Figure 17 (SEQ ID NO:27), Figure 19 (SEQ ID NO:29), Figure 22 (SEQ ID NO:32), Figure 24 (SEQ ID NO:35), Figure 26 (SEQ ID NO:40), Figure 29 (SEQ ID NO:46), Figure 31 (SEQ ID NO:51), Figure 33 (SEQ ID NO:56), Figure 35 (SEQ ID NO:61), Figure 37 (SEQ ID NO:66), Figure 40 (SEQ ID NO:72), Figure 46 (SEQ ID NO:83), Figure 48 (SEQ ID NO:94), Figure 50 (SEQ ID NO:96), Figure 52 (SEQ ID NO:98), Figure 56 (SEQ ID NO:102), Figure 63 (SEQ ID NO:112), Figure 65 (SEQ ID NO:114), Figure 67 (SEQ ID NO:116), Figure 69 (SEQ ID NO:118), Figure 71 (SEQ ID NO:123), Figure 73 (SEQ ID NO:128), Figure 75 (SEQ ID NO:134), Figure 78 (SEQ ID NO:137), Figure 82 (SEQ ID NO:145), Figure 84 (SEQ ID NO:147), Figure 87 (SEQ ID NO:150), Figure 89 (SEQ ID NO:152), Figure 92 (SEQ ID NO:155), Figure 94 (SEQ ID NO:157), Figure 96 (SEQ ID NO:159), Figure 98 (SEQ ID NO:164), Figure 100 (SEQ ID NO:166), Figure 102 (SEQ ID NO:168), Figure 104 (SEQ ID NO:170), Figure 108 (SEQ ID NO:174), Figure 110 (SEQ ID NO:176), Figure 112 (SEQ ID NO:178), Figure 114 (SEQ ID NO:180), Figure 116 (SEQ ID NO:182), Figure 119 (SEQ ID NO:188), Figure 121 (SEQ ID NO:193), Figure 124 (SEQ ID NO:196), Figure 126 (SEQ ID NO:198), Figure 128 (SEQ ID NO:200), Figure 130 (SEQ ID NO:202), Figure 132 (SEQ ID NO:204), Figure 134 (SEQ ID NO:206), Figure 136 (SEQ ID NO:208), Figure 138 (SEQ ID NO:210), Figure 140 (SEQ ID NO:212), Figure 143 (SEQ ID NO:215), Figure 146 (SEQ ID NO:218), Figure 148 (SEQ ID NO:220), Figure 150 (SEQ ID NO:222), Figure 152 (SEQ ID NO:224), Figure 154 (SEQ ID NO:226), Figure 156 (SEQ ID NO:228), Figure 158 (SEQ ID NO:230), Figure 160 (SEQ ID NO:235), Figure 162 (SEQ ID NO:240), Figure 164 (SEQ ID NO:245), Figure 166 (SEQ ID NO:247), Figure 168 (SEQ ID NO:249), Figure 170 (SEQ ID NO:252), Figure 173 (SEQ ID NO:255), Figure 175 (SEQ ID NO:257), Figure 177 (SEQ ID NO:259), Figure 179 (SEQ ID NO:261), Figure 181 (SEQ ID NO:263), Figure 183 (SEQ ID NO:265), Figure 185 (SEQ ID NO:267), Figure 187 (SEQ ID NO:269), Figure 189 (SEQ ID NO:271), Figure 191 (SEQ ID NO:273), Figure 193 (SEQ ID NO:275), Figure 195 (SEQ ID NO:277), Figure 197 (SEQ ID NO:280), Figure 199 (SEQ ID NO:282), Figure 201 (SEQ ID NO:284), Figure 203 (SEQ ID NO:286), Figure 205 (SEQ ID NO:288), Figure 207 (SEQ ID NO:290), Figure 209 (SEQ ID NO:292), Figure 211 (SEQ ID NO:294), Figure 213 (SEQ ID NO:296), Figure 215 (SEQ ID NO:298), Figure 217 (SEQ ID NO:300), Figure 219 (SEQ ID NO:302), Figure 225 (SEQ ID NO:308), Figure 227 (SEQ ID NO:313), Figure 229 (SEQ ID NO:318), Figure 232 (SEQ ID NO:325), Figure 234 (SEQ ID NO:333), Figure 237 (SEQ ID

NO:339), Figure 239 (SEQ ID NO:344), Figure 241 (SEQ ID NO:346), Figure 243 (SEQ ID NO:348), Figure 245 (SEQ ID NO:350), Figure 247 (SEQ ID NO:352), Figure 249 (SEQ ID NO:354), Figure 251 (SEQ ID NO:356), Figure 253 (SEQ ID NO:358), Figure 255 (SEQ ID NO:360), Figure 257 (SEQ ID NO:362), Figure 259 (SEQ ID NO:364), Figure 261 (SEQ ID NO:366), Figure 263 (SEQ ID NO:368), Figure 265 (SEQ ID NO:370), Figure 267 (SEQ ID NO:372), Figure 269 (SEQ ID NO:374), Figure 271 (SEQ ID NO:376), Figure 273 (SEQ ID NO:378), Figure 275 (SEQ ID NO:380), Figure 277 (SEQ ID NO:386), Figure 279 (SEQ ID NO:388), Figure 281 (SEQ ID NO:393), Figure 283 (SEQ ID NO:398), Figure 285 (SEQ ID NO:400), Figure 287 (SEQ ID NO:402), Figure 289 (SEQ ID NO:407), Figure 291 (SEQ ID NO:409), Figure 293 (SEQ ID NO:411), Figure 295 (SEQ ID NO:413), Figure 297 (SEQ ID NO:415), Figure 299 (SEQ ID NO:417), Figure 301 (SEQ ID NO:419), Figure 303 (SEQ ID NO:421), Figure 305 (SEQ ID NO:423), Figure 307 (SEQ ID NO:494), Figure 309 (SEQ ID NO:496), Figure 311 (SEQ ID NO:498), Figure 313 (SEQ ID NO:500), Figure 315 (SEQ ID NO:502), Figure 317 (SEQ ID NO:504), Figure 319 (SEQ ID NO:506), Figure 321 (SEQ ID NO:508), Figure 323 (SEQ ID NO:510), Figure 325 (SEQ ID NO:512), Figure 327 (SEQ ID NO:514) and Figure 329 (SEQ ID NO:516).

3. The nucleic acid of Claim 1, wherein said nucleotide sequence comprises a nucleotide sequence selected from the group consisting of the full-length coding sequence of the sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:5), Figure 5 (SEQ ID NO:7), Figure 8 (SEQ ID NO:13), Figure 11 (SEQ ID NO:19), Figure 14 (SEQ ID NO:22), Figure 17 (SEQ ID NO:27), Figure 19 (SEQ ID NO:29), Figure 22 (SEQ ID NO:32), Figure 24 (SEQ ID NO:35), Figure 26 (SEQ ID NO:40), Figure 29 (SEQ ID NO:46), Figure 31 (SEQ ID NO:51), Figure 33 (SEQ ID NO:56), Figure 35 (SEQ ID NO:61), Figure 37 (SEQ ID NO:66), Figure 40 (SEQ ID NO:72), Figure 46 (SEQ ID NO:83), Figure 48 (SEQ ID NO:94), Figure 50 (SEQ ID NO:96), Figure 52 (SEQ ID NO:98), Figure 56 (SEQ ID NO:102), Figure 63 (SEQ ID NO:112), Figure 65 (SEQ ID NO:114), Figure 67 (SEQ ID NO:116), Figure 69 (SEQ ID NO:118), Figure 71 (SEQ ID NO:123), Figure 73 (SEQ ID NO:128), Figure 75 (SEQ ID NO:134), Figure 78 (SEQ ID NO:137), Figure 82 (SEQ ID NO:145), Figure 84 (SEQ ID NO:147), Figure 87 (SEQ ID NO:150), Figure 89 (SEQ ID NO:152), Figure 92 (SEQ ID NO:155), Figure 94 (SEQ ID NO:157), Figure 96 (SEQ ID NO:159), Figure 98 (SEQ ID NO:164), Figure 100 (SEQ ID NO:166), Figure 102 (SEQ ID NO:168), Figure 104 (SEQ ID NO:170), Figure 108 (SEQ ID NO:174), Figure 110 (SEQ ID NO:176), Figure 112 (SEQ ID NO:178), Figure 114 (SEQ ID NO:180), Figure 116 (SEQ ID NO:182), Figure 119 (SEQ ID NO:188), Figure 121 (SEQ ID NO:193), Figure 124 (SEQ ID NO:196), Figure 126 (SEQ ID NO:198), Figure 128 (SEQ ID NO:200), Figure 130 (SEQ ID NO:202), Figure 132 (SEQ ID NO:204), Figure 134 (SEQ ID NO:206), Figure 136 (SEQ ID NO:208), Figure 138 (SEQ ID NO:210), Figure 140 (SEQ ID NO:212), Figure 143 (SEQ ID NO:215), Figure 146 (SEQ ID NO:218), Figure 148 (SEQ ID NO:220), Figure 150 (SEQ ID NO:222), Figure 152 (SEQ ID NO:224), Figure 154 (SEQ ID NO:226), Figure 156 (SEQ ID NO:228), Figure 158 (SEQ ID NO:230), Figure 160 (SEQ ID NO:235), Figure 162 (SEQ ID NO:240), Figure 164 (SEQ ID NO:245), Figure 166 (SEQ ID NO:247), Figure 168 (SEQ ID NO:249), Figure 170 (SEQ ID NO:252), Figure 173 (SEQ ID NO:255), Figure 175 (SEQ ID NO:257), Figure 177 (SEQ ID NO:259), Figure 179 (SEQ ID NO:261), Figure

181 (SEQ ID NO:263), Figure 183 (SEQ ID NO:265), Figure 185 (SEQ ID NO:267), Figure 187 (SEQ ID NO:269), Figure 189 (SEQ ID NO:271), Figure 191 (SEQ ID NO:273), Figure 193 (SEQ ID NO:275), Figure 195 (SEQ ID NO:277), Figure 197 (SEQ ID NO:280), Figure 199 (SEQ ID NO:282), Figure 201 (SEQ ID NO:284), Figure 203 (SEQ ID NO:286), Figure 205 (SEQ ID NO:288), Figure 207 (SEQ ID NO:290), Figure 209 (SEQ ID NO:292), Figure 211 (SEQ ID NO:294), Figure 213 (SEQ ID NO:296), Figure 215 (SEQ ID NO:298), Figure 217 (SEQ ID NO:300), Figure 219 (SEQ ID NO:302), Figure 225 (SEQ ID NO:308), Figure 227 (SEQ ID NO:313), Figure 229 (SEQ ID NO:318), Figure 232 (SEQ ID NO:325), Figure 234 (SEQ ID NO:333), Figure 237 (SEQ ID NO:339), Figure 239 (SEQ ID NO:344), Figure 241 (SEQ ID NO:346), Figure 243 (SEQ ID NO:348), Figure 245 (SEQ ID NO:350), Figure 247 (SEQ ID NO:352), Figure 249 (SEQ ID NO:354), Figure 251 (SEQ ID NO:356), Figure 253 (SEQ ID NO:358), Figure 255 (SEQ ID NO:360), Figure 257 (SEQ ID NO:362), Figure 259 (SEQ ID NO:364), Figure 261 (SEQ ID NO:366), Figure 263 (SEQ ID NO:368), Figure 265 (SEQ ID NO:370), Figure 267 (SEQ ID NO:372), Figure 269 (SEQ ID NO:374), Figure 271 (SEQ ID NO:376), Figure 273 (SEQ ID NO:378), Figure 275 (SEQ ID NO:380), Figure 277 (SEQ ID NO:386), Figure 279 (SEQ ID NO:388), Figure 281 (SEQ ID NO:393), Figure 283 (SEQ ID NO:398), Figure 285 (SEQ ID NO:400), Figure 287 (SEQ ID NO:402), Figure 289 (SEQ ID NO:407), Figure 291 (SEQ ID NO:409), Figure 293 (SEQ ID NO:411), Figure 295 (SEQ ID NO:413), Figure 297 (SEQ ID NO:415), Figure 299 (SEQ ID NO:417), Figure 301 (SEQ ID NO:419), Figure 303 (SEQ ID NO:421), Figure 305 (SEQ ID NO:423), Figure 307 (SEQ ID NO:494), Figure 309 (SEQ ID NO:496), Figure 311 (SEQ ID NO:498), Figure 313 (SEQ ID NO:500), Figure 315 (SEQ ID NO:502), Figure 317 (SEQ ID NO:504), Figure 319 (SEQ ID NO:506), Figure 321 (SEQ ID NO:508), Figure 323 (SEQ ID NO:510), Figure 325 (SEQ ID NO:512), Figure 327 (SEQ ID NO:514) and Figure 329 (SEQ ID NO:516).

4. Isolated nucleic acid which comprises the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 10.

5. A vector comprising the nucleic acid of Claim 1.

6. The vector of Claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.

7. A host cell comprising the vector of Claim 5.

8. The host cell of Claim 7 wherein said cell is a CHO cell.

9. The host cell of Claim 7 wherein said cell is an *E. coli*.

10. The host cell of Claim 7 wherein said cell is a yeast cell.

11. A process for producing a PRO polypeptides comprising culturing the host cell of Claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.

12. Isolated PRO polypeptide having at least 80% sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 9 (SEQ ID NO:14), Figure 12 (SEQ ID NO:20), Figure 15 (SEQ ID NO:23), Figure 18 (SEQ ID NO:28), Figure 20 (SEQ ID NO:30), Figure 23 (SEQ ID NO:33), Figure 25 (SEQ ID NO:36), Figure 27 (SEQ ID NO:41), Figure 30 (SEQ ID NO:47), Figure 32 (SEQ ID NO:52), Figure 34 (SEQ ID NO:57), Figure 36 (SEQ ID NO:62), Figure 38 (SEQ ID NO:67), Figure 41 (SEQ ID NO:73), Figure 47 (SEQ ID NO:84), Figure 49 (SEQ ID NO:95), Figure 51 (SEQ ID NO:97), Figure 53 (SEQ ID NO:99), Figure 57 (SEQ ID NO:103), Figure 64 (SEQ ID NO:113), Figure 66 (SEQ ID NO:115), Figure 68 (SEQ ID NO:117), Figure 70 (SEQ ID NO:119), Figure 72 (SEQ ID NO:124), Figure 74 (SEQ ID NO:129), Figure 76 (SEQ ID NO:135), Figure 79 (SEQ ID NO:138), Figure 83 (SEQ ID NO:146), Figure 85 (SEQ ID NO:148), Figure 88 (SEQ ID NO:151), Figure 90 (SEQ ID NO:153), Figure 93 (SEQ ID NO:156), Figure 95 (SEQ ID NO:158), Figure 97 (SEQ ID NO:160), Figure 99 (SEQ ID NO:165), Figure 101 (SEQ ID NO:167), Figure 103 (SEQ ID NO:169), Figure 105 (SEQ ID NO:171), Figure 109 (SEQ ID NO:175), Figure 111 (SEQ ID NO:177), Figure 113 (SEQ ID NO:179), Figure 115 (SEQ ID NO:181), Figure 117 (SEQ ID NO:183), Figure 120 (SEQ ID NO:189), Figure 122 (SEQ ID NO:194), Figure 125 (SEQ ID NO:197), Figure 127 (SEQ ID NO:199), Figure 129 (SEQ ID NO:201), Figure 131 (SEQ ID NO:203), Figure 133 (SEQ ID NO:205), Figure 135 (SEQ ID NO:207), Figure 137 (SEQ ID NO:209), Figure 139 (SEQ ID NO:211), Figure 141 (SEQ ID NO:213), Figure 144 (SEQ ID NO:216), Figure 147 (SEQ ID NO:219), Figure 149 (SEQ ID NO:221), Figure 151 (SEQ ID NO:223), Figure 153 (SEQ ID NO:225), Figure 155 (SEQ ID NO:227), Figure 157 (SEQ ID NO:229), Figure 159 (SEQ ID NO:231), Figure 161 (SEQ ID NO:236), Figure 163 (SEQ ID NO:241), Figure 165 (SEQ ID NO:246), Figure 167 (SEQ ID NO:248), Figure 169 (SEQ ID NO:250), Figure 171 (SEQ ID NO:253), Figure 174 (SEQ ID NO:256), Figure 176 (SEQ ID NO:258), Figure 178 (SEQ ID NO:260), Figure 180 (SEQ ID NO:262), Figure 182 (SEQ ID NO:264), Figure 184 (SEQ ID NO:266), Figure 186 (SEQ ID NO:268), Figure 188 (SEQ ID NO:270), Figure 190 (SEQ ID NO:272), Figure 192 (SEQ ID NO:274), Figure 194 (SEQ ID NO:276), Figure 196 (SEQ ID NO:278), Figure 198 (SEQ ID NO:281), Figure 200 (SEQ ID NO:283), Figure 202 (SEQ ID NO:285), Figure 204 (SEQ ID NO:287), Figure 206 (SEQ ID NO:289), Figure 208 (SEQ ID NO:291), Figure 210 (SEQ ID NO:293), Figure 212 (SEQ ID NO:295), Figure 214 (SEQ ID NO:297), Figure 216 (SEQ ID NO:299), Figure 218 (SEQ ID NO:301), Figure 220 (SEQ ID NO:303), Figure 226 (SEQ ID NO:309), Figure 228 (SEQ ID NO:314), Figure 230 (SEQ ID NO:319), Figure 233 (SEQ ID NO:326), Figure 235 (SEQ ID NO:334), Figure 238 (SEQ ID NO:340), Figure 240 (SEQ ID NO:345), Figure 242 (SEQ ID NO:347), Figure 244 (SEQ ID NO:349), Figure 246 (SEQ ID NO:351), Figure 248 (SEQ ID NO:353), Figure 250 (SEQ ID NO:355), Figure 252 (SEQ ID NO:357), Figure 254 (SEQ ID NO:359), Figure 256 (SEQ ID NO:361), Figure 258 (SEQ ID NO:363), Figure 260 (SEQ ID NO:365), Figure 262 (SEQ ID NO:367), Figure 264 (SEQ ID NO:369), Figure 266 (SEQ ID

NO:371), Figure 268 (SEQ ID NO:373), Figure 270 (SEQ ID NO:375), Figure 272 (SEQ ID NO:377), Figure 274 (SEQ ID NO:379), Figure 276 (SEQ ID NO:381), Figure 278 (SEQ ID NO:387), Figure 280 (SEQ ID NO:389), Figure 282 (SEQ ID NO:394), Figure 284 (SEQ ID NO:399), Figure 286 (SEQ ID NO:401), Figure 288 (SEQ ID NO:403), Figure 290 (SEQ ID NO:408), Figure 292 (SEQ ID NO:410), Figure 294 (SEQ ID NO:412), Figure 296 (SEQ ID NO:414), Figure 298 (SEQ ID NO:416), Figure 300 (SEQ ID NO:418), Figure 302 (SEQ ID NO:420), Figure 304 (SEQ ID NO:422), Figure 306 (SEQ ID NO:424), Figure 308 (SEQ ID NO:495), Figure 310 (SEQ ID NO:497), Figure 312 (SEQ ID NO:499), Figure 314 (SEQ ID NO:501), Figure 316 (SEQ ID NO:503), Figure 318 (SEQ ID NO:505), Figure 320 (SEQ ID NO:507), Figure 322 (SEQ ID NO:509), Figure 324 (SEQ ID NO:511), Figure 326 (SEQ ID NO:513), Figure 328 (SEQ ID NO:515) and Figure 330 (SEQ ID NO:517).

13. Isolated PRO polypeptide having at least 80% sequence identity to the amino acid sequence encoded by a nucleic acid molecule deposited under any ATCC accession number shown in Table 10.

14. A chimeric molecule comprising a polypeptide according to Claim 12 fused to a heterologous amino acid sequence.

15. The chimeric molecule of Claim 14 wherein said heterologous amino acid sequence is an epitope tag sequence.

16. The chimeric molecule of Claim 14 wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

17. An antibody which specifically binds to a PRO polypeptide according to Claim 12.

18. The antibody of Claim 17 wherein said antibody is a monoclonal antibody.

19. The antibody of Claim 17 wherein said antibody is a humanized antibody.

20. The antibody of Claim 17 wherein said antibody is an antibody fragment.

21. An isolated nucleic acid molecule which has at least 80 % sequence identity to a nucleic acid which comprises a nucleotide sequence selected from the group consisting of that shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:5), Figure 5 (SEQ ID NO:7), Figure 8 (SEQ ID NO:13), Figure 11 (SEQ ID NO:19), Figure 14 (SEQ ID NO:22), Figure 17 (SEQ ID NO:27), Figure 19 (SEQ ID NO:29), Figure 22 (SEQ ID NO:32), Figure 24 (SEQ ID NO:35), Figure 26 (SEQ ID NO:40), Figure 29 (SEQ ID NO:46), Figure 31 (SEQ ID NO:51), Figure 33 (SEQ ID NO:56), Figure 35 (SEQ ID NO:61), Figure 37 (SEQ ID NO:66), Figure 40 (SEQ ID NO:72), Figure 46 (SEQ ID NO:83), Figure 48 (SEQ ID NO:94), Figure 50

(SEQ ID NO:96), Figure 52 (SEQ ID NO:98), Figure 56 (SEQ ID NO:102), Figure 63 (SEQ ID NO:112), Figure 65 (SEQ ID NO:114), Figure 67 (SEQ ID NO:116), Figure 69 (SEQ ID NO:118), Figure 71 (SEQ ID NO:123), Figure 73 (SEQ ID NO:128), Figure 75 (SEQ ID NO:134), Figure 78 (SEQ ID NO:137), Figure 82 (SEQ ID NO:145), Figure 84 (SEQ ID NO:147), Figure 87 (SEQ ID NO:150), Figure 89 (SEQ ID NO:152), Figure 92 (SEQ ID NO:155), Figure 94 (SEQ ID NO:157), Figure 96 (SEQ ID NO:159), Figure 98 (SEQ ID NO:164), Figure 100 (SEQ ID NO:166), Figure 102 (SEQ ID NO:168), Figure 104 (SEQ ID NO:170), Figure 108 (SEQ ID NO:174), Figure 110 (SEQ ID NO:176), Figure 112 (SEQ ID NO:178), Figure 114 (SEQ ID NO:180), Figure 116 (SEQ ID NO:182), Figure 119 (SEQ ID NO:188), Figure 121 (SEQ ID NO:193), Figure 124 (SEQ ID NO:196), Figure 126 (SEQ ID NO:198), Figure 128 (SEQ ID NO:200), Figure 130 (SEQ ID NO:202), Figure 132 (SEQ ID NO:204), Figure 134 (SEQ ID NO:206), Figure 136 (SEQ ID NO:208), Figure 138 (SEQ ID NO:210), Figure 140 (SEQ ID NO:212), Figure 143 (SEQ ID NO:215), Figure 146 (SEQ ID NO:218), Figure 148 (SEQ ID NO:220), Figure 150 (SEQ ID NO:222), Figure 152 (SEQ ID NO:224), Figure 154 (SEQ ID NO:226), Figure 156 (SEQ ID NO:228), Figure 158 (SEQ ID NO:230), Figure 160 (SEQ ID NO:235), Figure 162 (SEQ ID NO:240), Figure 164 (SEQ ID NO:245), Figure 166 (SEQ ID NO:247), Figure 168 (SEQ ID NO:249), Figure 170 (SEQ ID NO:252), Figure 173 (SEQ ID NO:255), Figure 175 (SEQ ID NO:257), Figure 177 (SEQ ID NO:259), Figure 179 (SEQ ID NO:261), Figure 181 (SEQ ID NO:263), Figure 183 (SEQ ID NO:265), Figure 185 (SEQ ID NO:267), Figure 187 (SEQ ID NO:269), Figure 189 (SEQ ID NO:271), Figure 191 (SEQ ID NO:273), Figure 193 (SEQ ID NO:275), Figure 195 (SEQ ID NO:277), Figure 197 (SEQ ID NO:280), Figure 199 (SEQ ID NO:282), Figure 201 (SEQ ID NO:284), Figure 203 (SEQ ID NO:286), Figure 205 (SEQ ID NO:288), Figure 207 (SEQ ID NO:290), Figure 209 (SEQ ID NO:292), Figure 211 (SEQ ID NO:294), Figure 213 (SEQ ID NO:296), Figure 215 (SEQ ID NO:298), Figure 217 (SEQ ID NO:300), Figure 219 (SEQ ID NO:302), Figure 225 (SEQ ID NO:308), Figure 227 (SEQ ID NO:313), Figure 229 (SEQ ID NO:318), Figure 232 (SEQ ID NO:325), Figure 234 (SEQ ID NO:333), Figure 237 (SEQ ID NO:339), Figure 239 (SEQ ID NO:344), Figure 241 (SEQ ID NO:346), Figure 243 (SEQ ID NO:348), Figure 245 (SEQ ID NO:350), Figure 247 (SEQ ID NO:352), Figure 249 (SEQ ID NO:354), Figure 251 (SEQ ID NO:356), Figure 253 (SEQ ID NO:358), Figure 255 (SEQ ID NO:360), Figure 257 (SEQ ID NO:362), Figure 259 (SEQ ID NO:364), Figure 261 (SEQ ID NO:366), Figure 263 (SEQ ID NO:368), Figure 265 (SEQ ID NO:370), Figure 267 (SEQ ID NO:372), Figure 269 (SEQ ID NO:374), Figure 271 (SEQ ID NO:376), Figure 273 (SEQ ID NO:378), Figure 275 (SEQ ID NO:380), Figure 277 (SEQ ID NO:386), Figure 279 (SEQ ID NO:388), Figure 281 (SEQ ID NO:393), Figure 283 (SEQ ID NO:398), Figure 285 (SEQ ID NO:400), Figure 287 (SEQ ID NO:402), Figure 289 (SEQ ID NO:407), Figure 291 (SEQ ID NO:409), Figure 293 (SEQ ID NO:411), Figure 295 (SEQ ID NO:413), Figure 297 (SEQ ID NO:415), Figure 299 (SEQ ID NO:417), Figure 301 (SEQ ID NO:419), Figure 303 (SEQ ID NO:421), Figure 305 (SEQ ID NO:423), Figure 307 (SEQ ID NO:494), Figure 309 (SEQ ID NO:496), Figure 311 (SEQ ID NO:498), Figure 313 (SEQ ID NO:500), Figure 315 (SEQ ID NO:502), Figure 317 (SEQ ID NO:504), Figure 319 (SEQ ID NO:506), Figure 321 (SEQ ID NO:508), Figure 323 (SEQ ID NO:510), Figure 325 (SEQ ID NO:512), Figure 327 (SEQ ID NO:514) and Figure 329 (SEQ ID NO:516).

22. An isolated nucleic acid molecule which has at least 80% sequence identity to the full-length coding sequence of a nucleotide sequence selected from the group consisting of that shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:5), Figure 5 (SEQ ID NO:7), Figure 8 (SEQ ID NO:13), Figure 11 (SEQ ID NO:19), Figure 14 (SEQ ID NO:22), Figure 17 (SEQ ID NO:27), Figure 19 (SEQ ID NO:29), Figure 22 (SEQ ID NO:32), Figure 24 (SEQ ID NO:35), Figure 26 (SEQ ID NO:40), Figure 29 (SEQ ID NO:46), Figure 31 (SEQ ID NO:51), Figure 33 (SEQ ID NO:56), Figure 35 (SEQ ID NO:61), Figure 37 (SEQ ID NO:66), Figure 40 (SEQ ID NO:72), Figure 46 (SEQ ID NO:83), Figure 48 (SEQ ID NO:94), Figure 50 (SEQ ID NO:96), Figure 52 (SEQ ID NO:98), Figure 56 (SEQ ID NO:102), Figure 63 (SEQ ID NO:112), Figure 65 (SEQ ID NO:114), Figure 67 (SEQ ID NO:116), Figure 69 (SEQ ID NO:118), Figure 71 (SEQ ID NO:123), Figure 73 (SEQ ID NO:128), Figure 75 (SEQ ID NO:134), Figure 78 (SEQ ID NO:137), Figure 82 (SEQ ID NO:145), Figure 84 (SEQ ID NO:147), Figure 87 (SEQ ID NO:150), Figure 89 (SEQ ID NO:152), Figure 92 (SEQ ID NO:155), Figure 94 (SEQ ID NO:157), Figure 96 (SEQ ID NO:159), Figure 98 (SEQ ID NO:164), Figure 100 (SEQ ID NO:166), Figure 102 (SEQ ID NO:168), Figure 104 (SEQ ID NO:170), Figure 108 (SEQ ID NO:174), Figure 110 (SEQ ID NO:176), Figure 112 (SEQ ID NO:178), Figure 114 (SEQ ID NO:180), Figure 116 (SEQ ID NO:182), Figure 119 (SEQ ID NO:188), Figure 121 (SEQ ID NO:193), Figure 124 (SEQ ID NO:196), Figure 126 (SEQ ID NO:198), Figure 128 (SEQ ID NO:200), Figure 130 (SEQ ID NO:202), Figure 132 (SEQ ID NO:204), Figure 134 (SEQ ID NO:206), Figure 136 (SEQ ID NO:208), Figure 138 (SEQ ID NO:210), Figure 140 (SEQ ID NO:212), Figure 143 (SEQ ID NO:215), Figure 146 (SEQ ID NO:218), Figure 148 (SEQ ID NO:220), Figure 150 (SEQ ID NO:222), Figure 152 (SEQ ID NO:224), Figure 154 (SEQ ID NO:226), Figure 156 (SEQ ID NO:228), Figure 158 (SEQ ID NO:230), Figure 160 (SEQ ID NO:235), Figure 162 (SEQ ID NO:240), Figure 164 (SEQ ID NO:245), Figure 166 (SEQ ID NO:247), Figure 168 (SEQ ID NO:249), Figure 170 (SEQ ID NO:252), Figure 173 (SEQ ID NO:255), Figure 175 (SEQ ID NO:257), Figure 177 (SEQ ID NO:259), Figure 179 (SEQ ID NO:261), Figure 181 (SEQ ID NO:263), Figure 183 (SEQ ID NO:265), Figure 185 (SEQ ID NO:267), Figure 187 (SEQ ID NO:269), Figure 189 (SEQ ID NO:271), Figure 191 (SEQ ID NO:273), Figure 193 (SEQ ID NO:275), Figure 195 (SEQ ID NO:277), Figure 197 (SEQ ID NO:280), Figure 199 (SEQ ID NO:282), Figure 201 (SEQ ID NO:284), Figure 203 (SEQ ID NO:286), Figure 205 (SEQ ID NO:288), Figure 207 (SEQ ID NO:290), Figure 209 (SEQ ID NO:292), Figure 211 (SEQ ID NO:294), Figure 213 (SEQ ID NO:296), Figure 215 (SEQ ID NO:298), Figure 217 (SEQ ID NO:300), Figure 219 (SEQ ID NO:302), Figure 225 (SEQ ID NO:308), Figure 227 (SEQ ID NO:313), Figure 229 (SEQ ID NO:318), Figure 232 (SEQ ID NO:325), Figure 234 (SEQ ID NO:333), Figure 237 (SEQ ID NO:339), Figure 239 (SEQ ID NO:344), Figure 241 (SEQ ID NO:346), Figure 243 (SEQ ID NO:348), Figure 245 (SEQ ID NO:350), Figure 247 (SEQ ID NO:352), Figure 249 (SEQ ID NO:354), Figure 251 (SEQ ID NO:356), Figure 253 (SEQ ID NO:358), Figure 255 (SEQ ID NO:360), Figure 257 (SEQ ID NO:362), Figure 259 (SEQ ID NO:364), Figure 261 (SEQ ID NO:366), Figure 263 (SEQ ID NO:368), Figure 265 (SEQ ID NO:370), Figure 267 (SEQ ID NO:372), Figure 269 (SEQ ID NO:374), Figure 271 (SEQ ID NO:376), Figure 273 (SEQ ID NO:378), Figure 275 (SEQ ID NO:380), Figure 277 (SEQ ID NO:386), Figure 279 (SEQ ID NO:388), Figure 281 (SEQ ID NO:393), Figure 283 (SEQ ID NO:398), Figure 285 (SEQ ID NO:400), Figure 287 (SEQ ID NO:402), Figure 289 (SEQ ID NO:407), Figure 291 (SEQ ID NO:409), Figure



293 (SEQ ID NO:411), Figure 295 (SEQ ID NO:413), Figure 297 (SEQ ID NO:415), Figure 299 (SEQ ID NO:417), Figure 301 (SEQ ID NO:419), Figure 303 (SEQ ID NO:421), Figure 305 (SEQ ID NO:423), Figure 307 (SEQ ID NO:494), Figure 309 (SEQ ID NO:496), Figure 311 (SEQ ID NO:498), Figure 313 (SEQ ID NO:500), Figure 315 (SEQ ID NO:502), Figure 317 (SEQ ID NO:504), Figure 319 (SEQ ID NO:506), Figure 321 (SEQ ID NO:508), Figure 323 (SEQ ID NO:510), Figure 325 (SEQ ID NO:512), Figure 327 (SEQ ID NO:514) and Figure 329 (SEQ ID NO:516).

23. An isolated extracellular domain of of PRO polypeptide.

24. An isolated PRO polypeptide lacking its associated signal peptide.

25. An isolated polypeptide having at least about 80% amino acid sequence identity to an extracellular domain of of PRO polypeptide.

26. An isolated polypeptide having at least about 80% amino acid sequence identity to a PRO polypeptide lacking its associated signal peptide.

27. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 9 (SEQ ID NO:14), Figure 12 (SEQ ID NO:20), Figure 15 (SEQ ID NO:23), Figure 18 (SEQ ID NO:28), Figure 20 (SEQ ID NO:30), Figure 23 (SEQ ID NO:33), Figure 25 (SEQ ID NO:36), Figure 27 (SEQ ID NO:41), Figure 30 (SEQ ID NO:47), Figure 32 (SEQ ID NO:52), Figure 34 (SEQ ID NO:57), Figure 36 (SEQ ID NO:62), Figure 38 (SEQ ID NO:67), Figure 41 (SEQ ID NO:73), Figure 47 (SEQ ID NO:84), Figure 49 (SEQ ID NO:95), Figure 51 (SEQ ID NO:97), Figure 53 (SEQ ID NO:99), Figure 57 (SEQ ID NO:103), Figure 64 (SEQ ID NO:113), Figure 66 (SEQ ID NO:115), Figure 68 (SEQ ID NO:117), Figure 70 (SEQ ID NO:119), Figure 72 (SEQ ID NO:124), Figure 74 (SEQ ID NO:129), Figure 76 (SEQ ID NO:135), Figure 79 (SEQ ID NO:138), Figure 83 (SEQ ID NO:146), Figure 85 (SEQ ID NO:148), Figure 88 (SEQ ID NO:151), Figure 90 (SEQ ID NO:153), Figure 93 (SEQ ID NO:156), Figure 95 (SEQ ID NO:158), Figure 97 (SEQ ID NO:160), Figure 99 (SEQ ID NO:165), Figure 101 (SEQ ID NO:167), Figure 103 (SEQ ID NO:169), Figure 105 (SEQ ID NO:171), Figure 109 (SEQ ID NO:175), Figure 111 (SEQ ID NO:177), Figure 113 (SEQ ID NO:179), Figure 115 (SEQ ID NO:181), Figure 117 (SEQ ID NO:183), Figure 120 (SEQ ID NO:189), Figure 122 (SEQ ID NO:194), Figure 125 (SEQ ID NO:197), Figure 127 (SEQ ID NO:199), Figure 129 (SEQ ID NO:201), Figure 131 (SEQ ID NO:203), Figure 133 (SEQ ID NO:205), Figure 135 (SEQ ID NO:207), Figure 137 (SEQ ID NO:209), Figure 139 (SEQ ID NO:211), Figure 141 (SEQ ID NO:213), Figure 144 (SEQ ID NO:216), Figure 147 (SEQ ID NO:219), Figure 149 (SEQ ID NO:221), Figure 151 (SEQ ID NO:223), Figure 153 (SEQ ID NO:225), Figure 155 (SEQ ID NO:227), Figure 157 (SEQ ID NO:229), Figure 159 (SEQ ID NO:231), Figure 161 (SEQ ID NO:236), Figure 163 (SEQ ID NO:241), Figure 165 (SEQ ID NO:246), Figure 167 (SEQ ID NO:248), Figure

169 (SEQ ID NO:250), Figure 171 (SEQ ID NO:253), Figure 174 (SEQ ID NO:256), Figure 176 (SEQ ID NO:258), Figure 178 (SEQ ID NO:260), Figure 180 (SEQ ID NO:262), Figure 182 (SEQ ID NO:264), Figure 184 (SEQ ID NO:266), Figure 186 (SEQ ID NO:268), Figure 188 (SEQ ID NO:270), Figure 190 (SEQ ID NO:272), Figure 192 (SEQ ID NO:274), Figure 194 (SEQ ID NO:276), Figure 196 (SEQ ID NO:278), Figure 198 (SEQ ID NO:281), Figure 200 (SEQ ID NO:283), Figure 202 (SEQ ID NO:285), Figure 204 (SEQ ID NO:287), Figure 206 (SEQ ID NO:289), Figure 208 (SEQ ID NO:291), Figure 210 (SEQ ID NO:293), Figure 212 (SEQ ID NO:295), Figure 214 (SEQ ID NO:297), Figure 216 (SEQ ID NO:299), Figure 218 (SEQ ID NO:301), Figure 220 (SEQ ID NO:303), Figure 226 (SEQ ID NO:309), Figure 228 (SEQ ID NO:314), Figure 230 (SEQ ID NO:319), Figure 233 (SEQ ID NO:326), Figure 235 (SEQ ID NO:334), Figure 238 (SEQ ID NO:340), Figure 240 (SEQ ID NO:345), Figure 242 (SEQ ID NO:347), Figure 244 (SEQ ID NO:349), Figure 246 (SEQ ID NO:351), Figure 248 (SEQ ID NO:353), Figure 250 (SEQ ID NO:355), Figure 252 (SEQ ID NO:357), Figure 254 (SEQ ID NO:359), Figure 256 (SEQ ID NO:361), Figure 258 (SEQ ID NO:363), Figure 260 (SEQ ID NO:365), Figure 262 (SEQ ID NO:367), Figure 264 (SEQ ID NO:369), Figure 266 (SEQ ID NO:371), Figure 268 (SEQ ID NO:373), Figure 270 (SEQ ID NO:375), Figure 272 (SEQ ID NO:377), Figure 274 (SEQ ID NO:379), Figure 276 (SEQ ID NO:381), Figure 278 (SEQ ID NO:387), Figure 280 (SEQ ID NO:389), Figure 282 (SEQ ID NO:394), Figure 284 (SEQ ID NO:399), Figure 286 (SEQ ID NO:401), Figure 288 (SEQ ID NO:403), Figure 290 (SEQ ID NO:408), Figure 292 (SEQ ID NO:410), Figure 294 (SEQ ID NO:412), Figure 296 (SEQ ID NO:414), Figure 298 (SEQ ID NO:416), Figure 300 (SEQ ID NO:418), Figure 302 (SEQ ID NO:420), Figure 304 (SEQ ID NO:422), Figure 306 (SEQ ID NO:424), Figure 308 (SEQ ID NO:495), Figure 310 (SEQ ID NO:497), Figure 312 (SEQ ID NO:499), Figure 314 (SEQ ID NO:501), Figure 316 (SEQ ID NO:503), Figure 318 (SEQ ID NO:505), Figure 320 (SEQ ID NO:507), Figure 322 (SEQ ID NO:509), Figure 324 (SEQ ID NO:511), Figure 326 (SEQ ID NO:513), Figure 328 (SEQ ID NO:515) or Figure 330 (SEQ ID NO:517), lacking its associated signal peptide;

(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 9 (SEQ ID NO:14), Figure 12 (SEQ ID NO:20), Figure 15 (SEQ ID NO:23), Figure 18 (SEQ ID NO:28), Figure 20 (SEQ ID NO:30), Figure 23 (SEQ ID NO:33), Figure 25 (SEQ ID NO:36), Figure 27 (SEQ ID NO:41), Figure 30 (SEQ ID NO:47), Figure 32 (SEQ ID NO:52), Figure 34 (SEQ ID NO:57), Figure 36 (SEQ ID NO:62), Figure 38 (SEQ ID NO:67), Figure 41 (SEQ ID NO:73), Figure 47 (SEQ ID NO:84), Figure 49 (SEQ ID NO:95), Figure 51 (SEQ ID NO:97), Figure 53 (SEQ ID NO:99), Figure 57 (SEQ ID NO:103), Figure 64 (SEQ ID NO:113), Figure 66 (SEQ ID NO:115), Figure 68 (SEQ ID NO:117), Figure 70 (SEQ ID NO:119), Figure 72 (SEQ ID NO:124), Figure 74 (SEQ ID NO:129), Figure 76 (SEQ ID NO:135), Figure 79 (SEQ ID NO:138), Figure 83 (SEQ ID NO:146), Figure 85 (SEQ ID NO:148), Figure 88 (SEQ ID NO:151), Figure 90 (SEQ ID NO:153), Figure 93 (SEQ ID NO:156), Figure 95 (SEQ ID NO:158), Figure 97 (SEQ ID NO:160), Figure 99 (SEQ ID NO:165), Figure 101 (SEQ ID NO:167), Figure 103 (SEQ ID NO:169), Figure 105 (SEQ ID NO:171), Figure 109 (SEQ ID NO:175), Figure 111 (SEQ ID NO:177), Figure 113 (SEQ ID NO:179), Figure 115 (SEQ ID NO:181), Figure 117 (SEQ ID NO:183), Figure 120 (SEQ ID NO:189), Figure 122 (SEQ ID NO:194), Figure 125 (SEQ ID NO:197), Figure 127 (SEQ ID NO:199), Figure 129 (SEQ ID

NO:201), Figure 131 (SEQ ID NO:203), Figure 133 (SEQ ID NO:205), Figure 135 (SEQ ID NO:207), Figure 137 (SEQ ID NO:209), Figure 139 (SEQ ID NO:211), Figure 141 (SEQ ID NO:213), Figure 144 (SEQ ID NO:216), Figure 147 (SEQ ID NO:219), Figure 149 (SEQ ID NO:221), Figure 151 (SEQ ID NO:223), Figure 153 (SEQ ID NO:225), Figure 155 (SEQ ID NO:227), Figure 157 (SEQ ID NO:229), Figure 159 (SEQ ID NO:231), Figure 161 (SEQ ID NO:236), Figure 163 (SEQ ID NO:241), Figure 165 (SEQ ID NO:246), Figure 167 (SEQ ID NO:248), Figure 169 (SEQ ID NO:250), Figure 171 (SEQ ID NO:253), Figure 174 (SEQ ID NO:256), Figure 176 (SEQ ID NO:258), Figure 178 (SEQ ID NO:260), Figure 180 (SEQ ID NO:262), Figure 182 (SEQ ID NO:264), Figure 184 (SEQ ID NO:266), Figure 186 (SEQ ID NO:268), Figure 188 (SEQ ID NO:270), Figure 190 (SEQ ID NO:272), Figure 192 (SEQ ID NO:274), Figure 194 (SEQ ID NO:276), Figure 196 (SEQ ID NO:278), Figure 198 (SEQ ID NO:281), Figure 200 (SEQ ID NO:283), Figure 202 (SEQ ID NO:285), Figure 204 (SEQ ID NO:287), Figure 206 (SEQ ID NO:289), Figure 208 (SEQ ID NO:291), Figure 210 (SEQ ID NO:293), Figure 212 (SEQ ID NO:295), Figure 214 (SEQ ID NO:297), Figure 216 (SEQ ID NO:299), Figure 218 (SEQ ID NO:301), Figure 220 (SEQ ID NO:303), Figure 226 (SEQ ID NO:309), Figure 228 (SEQ ID NO:314), Figure 230 (SEQ ID NO:319), Figure 233 (SEQ ID NO:326), Figure 235 (SEQ ID NO:334), Figure 238 (SEQ ID NO:340), Figure 240 (SEQ ID NO:345), Figure 242 (SEQ ID NO:347), Figure 244 (SEQ ID NO:349), Figure 246 (SEQ ID NO:351), Figure 248 (SEQ ID NO:353), Figure 250 (SEQ ID NO:355), Figure 252 (SEQ ID NO:357), Figure 254 (SEQ ID NO:359), Figure 256 (SEQ ID NO:361), Figure 258 (SEQ ID NO:363), Figure 260 (SEQ ID NO:365), Figure 262 (SEQ ID NO:367), Figure 264 (SEQ ID NO:369), Figure 266 (SEQ ID NO:371), Figure 268 (SEQ ID NO:373), Figure 270 (SEQ ID NO:375), Figure 272 (SEQ ID NO:377), Figure 274 (SEQ ID NO:379), Figure 276 (SEQ ID NO:381), Figure 278 (SEQ ID NO:387), Figure 280 (SEQ ID NO:389), Figure 282 (SEQ ID NO:394), Figure 284 (SEQ ID NO:399), Figure 286 (SEQ ID NO:401), Figure 288 (SEQ ID NO:403), Figure 290 (SEQ ID NO:408), Figure 292 (SEQ ID NO:410), Figure 294 (SEQ ID NO:412), Figure 296 (SEQ ID NO:414), Figure 298 (SEQ ID NO:416), Figure 300 (SEQ ID NO:418), Figure 302 (SEQ ID NO:420), Figure 304 (SEQ ID NO:422), Figure 306 (SEQ ID NO:424), Figure 308 (SEQ ID NO:495), Figure 310 (SEQ ID NO:497), Figure 312 (SEQ ID NO:499), Figure 314 (SEQ ID NO:501), Figure 316 (SEQ ID NO:503), Figure 318 (SEQ ID NO:505), Figure 320 (SEQ ID NO:507), Figure 322 (SEQ ID NO:509), Figure 324 (SEQ ID NO:511), Figure 326 (SEQ ID NO:513), Figure 328 (SEQ ID NO:515) or Figure 330 (SEQ ID NO:517), with its associated signal peptide; or

(c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 9 (SEQ ID NO:14), Figure 12 (SEQ ID NO:20), Figure 15 (SEQ ID NO:23), Figure 18 (SEQ ID NO:28), Figure 20 (SEQ ID NO:30), Figure 23 (SEQ ID NO:33), Figure 25 (SEQ ID NO:36), Figure 27 (SEQ ID NO:41), Figure 30 (SEQ ID NO:47), Figure 32 (SEQ ID NO:52), Figure 34 (SEQ ID NO:57), Figure 36 (SEQ ID NO:62), Figure 38 (SEQ ID NO:67), Figure 41 (SEQ ID NO:73), Figure 47 (SEQ ID NO:84), Figure 49 (SEQ ID NO:95), Figure 51 (SEQ ID NO:97), Figure 53 (SEQ ID NO:99), Figure 57 (SEQ ID NO:103), Figure 64 (SEQ ID NO:113), Figure 66 (SEQ ID NO:115), Figure 68 (SEQ ID NO:117), Figure 70 (SEQ ID NO:119), Figure 72 (SEQ ID NO:124), Figure 74 (SEQ ID NO:129), Figure 76 (SEQ ID NO:135), Figure 79 (SEQ ID NO:138), Figure 83 (SEQ ID NO:146), Figure 85 (SEQ ID NO:148), Figure 88 (SEQ ID NO:151), Figure

90 (SEQ ID NO:153), Figure 93 (SEQ ID NO:156), Figure 95 (SEQ ID NO:158), Figure 97 (SEQ ID NO:160), Figure 99 (SEQ ID NO:165), Figure 101 (SEQ ID NO:167), Figure 103 (SEQ ID NO:169), Figure 105 (SEQ ID NO:171), Figure 109 (SEQ ID NO:175), Figure 111 (SEQ ID NO:177), Figure 113 (SEQ ID NO:179), Figure 115 (SEQ ID NO:181), Figure 117 (SEQ ID NO:183), Figure 120 (SEQ ID NO:189), Figure 122 (SEQ ID NO:194), Figure 125 (SEQ ID NO:197), Figure 127 (SEQ ID NO:199), Figure 129 (SEQ ID NO:201), Figure 131 (SEQ ID NO:203), Figure 133 (SEQ ID NO:205), Figure 135 (SEQ ID NO:207), Figure 137 (SEQ ID NO:209), Figure 139 (SEQ ID NO:211), Figure 141 (SEQ ID NO:213), Figure 144 (SEQ ID NO:216), Figure 147 (SEQ ID NO:219), Figure 149 (SEQ ID NO:221), Figure 151 (SEQ ID NO:223), Figure 153 (SEQ ID NO:225), Figure 155 (SEQ ID NO:227), Figure 157 (SEQ ID NO:229), Figure 159 (SEQ ID NO:231), Figure 161 (SEQ ID NO:236), Figure 163 (SEQ ID NO:241), Figure 165 (SEQ ID NO:246), Figure 167 (SEQ ID NO:248), Figure 169 (SEQ ID NO:250), Figure 171 (SEQ ID NO:253), Figure 174 (SEQ ID NO:256), Figure 176 (SEQ ID NO:258), Figure 178 (SEQ ID NO:260), Figure 180 (SEQ ID NO:262), Figure 182 (SEQ ID NO:264), Figure 184 (SEQ ID NO:266), Figure 186 (SEQ ID NO:268), Figure 188 (SEQ ID NO:270), Figure 190 (SEQ ID NO:272), Figure 192 (SEQ ID NO:274), Figure 194 (SEQ ID NO:276), Figure 196 (SEQ ID NO:278), Figure 198 (SEQ ID NO:281), Figure 200 (SEQ ID NO:283), Figure 202 (SEQ ID NO:285), Figure 204 (SEQ ID NO:287), Figure 206 (SEQ ID NO:289), Figure 208 (SEQ ID NO:291), Figure 210 (SEQ ID NO:293), Figure 212 (SEQ ID NO:295), Figure 214 (SEQ ID NO:297), Figure 216 (SEQ ID NO:299), Figure 218 (SEQ ID NO:301), Figure 220 (SEQ ID NO:303), Figure 226 (SEQ ID NO:309), Figure 228 (SEQ ID NO:314), Figure 230 (SEQ ID NO:319), Figure 233 (SEQ ID NO:326), Figure 235 (SEQ ID NO:334), Figure 238 (SEQ ID NO:340), Figure 240 (SEQ ID NO:345), Figure 242 (SEQ ID NO:347), Figure 244 (SEQ ID NO:349), Figure 246 (SEQ ID NO:351), Figure 248 (SEQ ID NO:353), Figure 250 (SEQ ID NO:355), Figure 252 (SEQ ID NO:357), Figure 254 (SEQ ID NO:359), Figure 256 (SEQ ID NO:361), Figure 258 (SEQ ID NO:363), Figure 260 (SEQ ID NO:365), Figure 262 (SEQ ID NO:367), Figure 264 (SEQ ID NO:369), Figure 266 (SEQ ID NO:371), Figure 268 (SEQ ID NO:373), Figure 270 (SEQ ID NO:375), Figure 272 (SEQ ID NO:377), Figure 274 (SEQ ID NO:379), Figure 276 (SEQ ID NO:381), Figure 278 (SEQ ID NO:387), Figure 280 (SEQ ID NO:389), Figure 282 (SEQ ID NO:394), Figure 284 (SEQ ID NO:399), Figure 286 (SEQ ID NO:401), Figure 288 (SEQ ID NO:403), Figure 290 (SEQ ID NO:408), Figure 292 (SEQ ID NO:410), Figure 294 (SEQ ID NO:412), Figure 296 (SEQ ID NO:414), Figure 298 (SEQ ID NO:416), Figure 300 (SEQ ID NO:418), Figure 302 (SEQ ID NO:420), Figure 304 (SEQ ID NO:422), Figure 306 (SEQ ID NO:424), Figure 308 (SEQ ID NO:495), Figure 310 (SEQ ID NO:497), Figure 312 (SEQ ID NO:499), Figure 314 (SEQ ID NO:501), Figure 316 (SEQ ID NO:503), Figure 318 (SEQ ID NO:505), Figure 320 (SEQ ID NO:507), Figure 322 (SEQ ID NO:509), Figure 324 (SEQ ID NO:511), Figure 326 (SEQ ID NO:513), Figure 328 (SEQ ID NO:515) or Figure 330 (SEQ ID NO:517), lacking its associated signal peptide.

28. An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 9 (SEQ ID NO:14), Figure 12 (SEQ ID NO:20), Figure 15 (SEQ ID NO:23), Figure 18 (SEQ ID NO:28), Figure 20 (SEQ ID NO:30), Figure 23 (SEQ ID NO:33), Figure 25 (SEQ ID NO:36),

Figure 27 (SEQ ID NO:41), Figure 30 (SEQ ID NO:47), Figure 32 (SEQ ID NO:52), Figure 34 (SEQ ID NO:57), Figure 36 (SEQ ID NO:62), Figure 38 (SEQ ID NO:67), Figure 41 (SEQ ID NO:73), Figure 47 (SEQ ID NO:84), Figure 49 (SEQ ID NO:95), Figure 51 (SEQ ID NO:97), Figure 53 (SEQ ID NO:99), Figure 57 (SEQ ID NO:103), Figure 64 (SEQ ID NO:113), Figure 66 (SEQ ID NO:115), Figure 68 (SEQ ID NO:117), Figure 70 (SEQ ID NO:119), Figure 72 (SEQ ID NO:124), Figure 74 (SEQ ID NO:129), Figure 76 (SEQ ID NO:135), Figure 79 (SEQ ID NO:138), Figure 83 (SEQ ID NO:146), Figure 85 (SEQ ID NO:148), Figure 88 (SEQ ID NO:151), Figure 90 (SEQ ID NO:153), Figure 93 (SEQ ID NO:156), Figure 95 (SEQ ID NO:158), Figure 97 (SEQ ID NO:160), Figure 99 (SEQ ID NO:165), Figure 101 (SEQ ID NO:167), Figure 103 (SEQ ID NO:169), Figure 105 (SEQ ID NO:171), Figure 109 (SEQ ID NO:175), Figure 111 (SEQ ID NO:177), Figure 113 (SEQ ID NO:179), Figure 115 (SEQ ID NO:181), Figure 117 (SEQ ID NO:183), Figure 120 (SEQ ID NO:189), Figure 122 (SEQ ID NO:194), Figure 125 (SEQ ID NO:197), Figure 127 (SEQ ID NO:199), Figure 129 (SEQ ID NO:201), Figure 131 (SEQ ID NO:203), Figure 133 (SEQ ID NO:205), Figure 135 (SEQ ID NO:207), Figure 137 (SEQ ID NO:209), Figure 139 (SEQ ID NO:211), Figure 141 (SEQ ID NO:213), Figure 144 (SEQ ID NO:216), Figure 147 (SEQ ID NO:219), Figure 149 (SEQ ID NO:221), Figure 151 (SEQ ID NO:223), Figure 153 (SEQ ID NO:225), Figure 155 (SEQ ID NO:227), Figure 157 (SEQ ID NO:229), Figure 159 (SEQ ID NO:231), Figure 161 (SEQ ID NO:236), Figure 163 (SEQ ID NO:241), Figure 165 (SEQ ID NO:246), Figure 167 (SEQ ID NO:248), Figure 169 (SEQ ID NO:250), Figure 171 (SEQ ID NO:253), Figure 174 (SEQ ID NO:256), Figure 176 (SEQ ID NO:258), Figure 178 (SEQ ID NO:260), Figure 180 (SEQ ID NO:262), Figure 182 (SEQ ID NO:264), Figure 184 (SEQ ID NO:266), Figure 186 (SEQ ID NO:268), Figure 188 (SEQ ID NO:270), Figure 190 (SEQ ID NO:272), Figure 192 (SEQ ID NO:274), Figure 194 (SEQ ID NO:276), Figure 196 (SEQ ID NO:278), Figure 198 (SEQ ID NO:281), Figure 200 (SEQ ID NO:283), Figure 202 (SEQ ID NO:285), Figure 204 (SEQ ID NO:287), Figure 206 (SEQ ID NO:289), Figure 208 (SEQ ID NO:291), Figure 210 (SEQ ID NO:293), Figure 212 (SEQ ID NO:295), Figure 214 (SEQ ID NO:297), Figure 216 (SEQ ID NO:299), Figure 218 (SEQ ID NO:301), Figure 220 (SEQ ID NO:303), Figure 226 (SEQ ID NO:309), Figure 228 (SEQ ID NO:314), Figure 230 (SEQ ID NO:319), Figure 233 (SEQ ID NO:326), Figure 235 (SEQ ID NO:334), Figure 238 (SEQ ID NO:340), Figure 240 (SEQ ID NO:345), Figure 242 (SEQ ID NO:347), Figure 244 (SEQ ID NO:349), Figure 246 (SEQ ID NO:351), Figure 248 (SEQ ID NO:353), Figure 250 (SEQ ID NO:355), Figure 252 (SEQ ID NO:357), Figure 254 (SEQ ID NO:359), Figure 256 (SEQ ID NO:361), Figure 258 (SEQ ID NO:363), Figure 260 (SEQ ID NO:365), Figure 262 (SEQ ID NO:367), Figure 264 (SEQ ID NO:369), Figure 266 (SEQ ID NO:371), Figure 268 (SEQ ID NO:373), Figure 270 (SEQ ID NO:375), Figure 272 (SEQ ID NO:377), Figure 274 (SEQ ID NO:379), Figure 276 (SEQ ID NO:381), Figure 278 (SEQ ID NO:387), Figure 280 (SEQ ID NO:389), Figure 282 (SEQ ID NO:394), Figure 284 (SEQ ID NO:399), Figure 286 (SEQ ID NO:401), Figure 288 (SEQ ID NO:403), Figure 290 (SEQ ID NO:408), Figure 292 (SEQ ID NO:410), Figure 294 (SEQ ID NO:412), Figure 296 (SEQ ID NO:414), Figure 298 (SEQ ID NO:416), Figure 300 (SEQ ID NO:418), Figure 302 (SEQ ID NO:420), Figure 304 (SEQ ID NO:422), Figure 306 (SEQ ID NO:424), Figure 308 (SEQ ID NO:495), Figure 310 (SEQ ID NO:497), Figure 312 (SEQ ID NO:499), Figure 314 (SEQ ID NO:501), Figure 316 (SEQ ID NO:503), Figure 318 (SEQ ID NO:505), Figure 320 (SEQ ID NO:507), Figure 322 (SEQ ID NO:509), Figure 324 (SEQ ID

NO:511), Figure 326 (SEQ ID NO:513), Figure 328 (SEQ ID NO:515) or Figure 330 (SEQ ID NO:517), lacking its associated signal peptide;

(b) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 9 (SEQ ID NO:14), Figure 12 (SEQ ID NO:20), Figure 15 (SEQ ID NO:23), Figure 18 (SEQ ID NO:28), Figure 20 (SEQ ID NO:30), Figure 23 (SEQ ID NO:33), Figure 25 (SEQ ID NO:36), Figure 27 (SEQ ID NO:41), Figure 30 (SEQ ID NO:47), Figure 32 (SEQ ID NO:52), Figure 34 (SEQ ID NO:57), Figure 36 (SEQ ID NO:62), Figure 38 (SEQ ID NO:67), Figure 41 (SEQ ID NO:73), Figure 47 (SEQ ID NO:84), Figure 49 (SEQ ID NO:95), Figure 51 (SEQ ID NO:97), Figure 53 (SEQ ID NO:99), Figure 57 (SEQ ID NO:103), Figure 64 (SEQ ID NO:113), Figure 66 (SEQ ID NO:115), Figure 68 (SEQ ID NO:117), Figure 70 (SEQ ID NO:119), Figure 72 (SEQ ID NO:124), Figure 74 (SEQ ID NO:129), Figure 76 (SEQ ID NO:135), Figure 79 (SEQ ID NO:138), Figure 83 (SEQ ID NO:146), Figure 85 (SEQ ID NO:148), Figure 88 (SEQ ID NO:151), Figure 90 (SEQ ID NO:153), Figure 93 (SEQ ID NO:156), Figure 95 (SEQ ID NO:158), Figure 97 (SEQ ID NO:160), Figure 99 (SEQ ID NO:165), Figure 101 (SEQ ID NO:167), Figure 103 (SEQ ID NO:169), Figure 105 (SEQ ID NO:171), Figure 109 (SEQ ID NO:175), Figure 111 (SEQ ID NO:177), Figure 113 (SEQ ID NO:179), Figure 115 (SEQ ID NO:181), Figure 117 (SEQ ID NO:183), Figure 120 (SEQ ID NO:189), Figure 122 (SEQ ID NO:194), Figure 125 (SEQ ID NO:197), Figure 127 (SEQ ID NO:199), Figure 129 (SEQ ID NO:201), Figure 131 (SEQ ID NO:203), Figure 133 (SEQ ID NO:205), Figure 135 (SEQ ID NO:207), Figure 137 (SEQ ID NO:209), Figure 139 (SEQ ID NO:211), Figure 141 (SEQ ID NO:213), Figure 144 (SEQ ID NO:216), Figure 147 (SEQ ID NO:219), Figure 149 (SEQ ID NO:221), Figure 151 (SEQ ID NO:223), Figure 153 (SEQ ID NO:225), Figure 155 (SEQ ID NO:227), Figure 157 (SEQ ID NO:229), Figure 159 (SEQ ID NO:231), Figure 161 (SEQ ID NO:236), Figure 163 (SEQ ID NO:241), Figure 165 (SEQ ID NO:246), Figure 167 (SEQ ID NO:248), Figure 169 (SEQ ID NO:250), Figure 171 (SEQ ID NO:253), Figure 174 (SEQ ID NO:256), Figure 176 (SEQ ID NO:258), Figure 178 (SEQ ID NO:260), Figure 180 (SEQ ID NO:262), Figure 182 (SEQ ID NO:264), Figure 184 (SEQ ID NO:266), Figure 186 (SEQ ID NO:268), Figure 188 (SEQ ID NO:270), Figure 190 (SEQ ID NO:272), Figure 192 (SEQ ID NO:274), Figure 194 (SEQ ID NO:276), Figure 196 (SEQ ID NO:278), Figure 198 (SEQ ID NO:281), Figure 200 (SEQ ID NO:283), Figure 202 (SEQ ID NO:285), Figure 204 (SEQ ID NO:287), Figure 206 (SEQ ID NO:289), Figure 208 (SEQ ID NO:291), Figure 210 (SEQ ID NO:293), Figure 212 (SEQ ID NO:295), Figure 214 (SEQ ID NO:297), Figure 216 (SEQ ID NO:299), Figure 218 (SEQ ID NO:301), Figure 220 (SEQ ID NO:303), Figure 226 (SEQ ID NO:309), Figure 228 (SEQ ID NO:314), Figure 230 (SEQ ID NO:319), Figure 233 (SEQ ID NO:326), Figure 235 (SEQ ID NO:334), Figure 238 (SEQ ID NO:340), Figure 240 (SEQ ID NO:345), Figure 242 (SEQ ID NO:347), Figure 244 (SEQ ID NO:349), Figure 246 (SEQ ID NO:351), Figure 248 (SEQ ID NO:353), Figure 250 (SEQ ID NO:355), Figure 252 (SEQ ID NO:357), Figure 254 (SEQ ID NO:359), Figure 256 (SEQ ID NO:361), Figure 258 (SEQ ID NO:363), Figure 260 (SEQ ID NO:365), Figure 262 (SEQ ID NO:367), Figure 264 (SEQ ID NO:369), Figure 266 (SEQ ID NO:371), Figure 268 (SEQ ID NO:373), Figure 270 (SEQ ID NO:375), Figure 272 (SEQ ID NO:377), Figure 274 (SEQ ID NO:379), Figure 276 (SEQ ID NO:381), Figure 278 (SEQ ID NO:387), Figure 280 (SEQ ID NO:389), Figure 282 (SEQ ID NO:394), Figure 284 (SEQ ID NO:399), Figure 286 (SEQ ID NO:401), Figure 288 (SEQ ID

NO:403), Figure 290 (SEQ ID NO:408), Figure 292 (SEQ ID NO:410), Figure 294 (SEQ ID NO:412), Figure 296 (SEQ ID NO:414), Figure 298 (SEQ ID NO:416), Figure 300 (SEQ ID NO:418), Figure 302 (SEQ ID NO:420), Figure 304 (SEQ ID NO:422), Figure 306 (SEQ ID NO:424), Figure 308 (SEQ ID NO:495), Figure 310 (SEQ ID NO:497), Figure 312 (SEQ ID NO:499), Figure 314 (SEQ ID NO:501), Figure 316 (SEQ ID NO:503), Figure 318 (SEQ ID NO:505), Figure 320 (SEQ ID NO:507), Figure 322 (SEQ ID NO:509), Figure 324 (SEQ ID NO:511), Figure 326 (SEQ ID NO:513), Figure 328 (SEQ ID NO:515) or Figure 330 (SEQ ID NO:517), with its associated signal peptide; or

(c) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 9 (SEQ ID NO:14), Figure 12 (SEQ ID NO:20), Figure 15 (SEQ ID NO:23), Figure 18 (SEQ ID NO:28), Figure 20 (SEQ ID NO:30), Figure 23 (SEQ ID NO:33), Figure 25 (SEQ ID NO:36), Figure 27 (SEQ ID NO:41), Figure 30 (SEQ ID NO:47), Figure 32 (SEQ ID NO:52), Figure 34 (SEQ ID NO:57), Figure 36 (SEQ ID NO:62), Figure 38 (SEQ ID NO:67), Figure 41 (SEQ ID NO:73), Figure 47 (SEQ ID NO:84), Figure 49 (SEQ ID NO:95), Figure 51 (SEQ ID NO:97), Figure 53 (SEQ ID NO:99), Figure 57 (SEQ ID NO:103), Figure 64 (SEQ ID NO:113), Figure 66 (SEQ ID NO:115), Figure 68 (SEQ ID NO:117), Figure 70 (SEQ ID NO:119), Figure 72 (SEQ ID NO:124), Figure 74 (SEQ ID NO:129), Figure 76 (SEQ ID NO:135), Figure 79 (SEQ ID NO:138), Figure 83 (SEQ ID NO:146), Figure 85 (SEQ ID NO:148), Figure 88 (SEQ ID NO:151), Figure 90 (SEQ ID NO:153), Figure 93 (SEQ ID NO:156), Figure 95 (SEQ ID NO:158), Figure 97 (SEQ ID NO:160), Figure 99 (SEQ ID NO:165), Figure 101 (SEQ ID NO:167), Figure 103 (SEQ ID NO:169), Figure 105 (SEQ ID NO:171), Figure 109 (SEQ ID NO:175), Figure 111 (SEQ ID NO:177), Figure 113 (SEQ ID NO:179), Figure 115 (SEQ ID NO:181), Figure 117 (SEQ ID NO:183), Figure 120 (SEQ ID NO:189), Figure 122 (SEQ ID NO:194), Figure 125 (SEQ ID NO:197), Figure 127 (SEQ ID NO:199), Figure 129 (SEQ ID NO:201), Figure 131 (SEQ ID NO:203), Figure 133 (SEQ ID NO:205), Figure 135 (SEQ ID NO:207), Figure 137 (SEQ ID NO:209), Figure 139 (SEQ ID NO:211), Figure 141 (SEQ ID NO:213), Figure 144 (SEQ ID NO:216), Figure 147 (SEQ ID NO:219), Figure 149 (SEQ ID NO:221), Figure 151 (SEQ ID NO:223), Figure 153 (SEQ ID NO:225), Figure 155 (SEQ ID NO:227), Figure 157 (SEQ ID NO:229), Figure 159 (SEQ ID NO:231), Figure 161 (SEQ ID NO:236), Figure 163 (SEQ ID NO:241), Figure 165 (SEQ ID NO:246), Figure 167 (SEQ ID NO:248), Figure 169 (SEQ ID NO:250), Figure 171 (SEQ ID NO:253), Figure 174 (SEQ ID NO:256), Figure 176 (SEQ ID NO:258), Figure 178 (SEQ ID NO:260), Figure 180 (SEQ ID NO:262), Figure 182 (SEQ ID NO:264), Figure 184 (SEQ ID NO:266), Figure 186 (SEQ ID NO:268), Figure 188 (SEQ ID NO:270), Figure 190 (SEQ ID NO:272), Figure 192 (SEQ ID NO:274), Figure 194 (SEQ ID NO:276), Figure 196 (SEQ ID NO:278), Figure 198 (SEQ ID NO:281), Figure 200 (SEQ ID NO:283), Figure 202 (SEQ ID NO:285), Figure 204 (SEQ ID NO:287), Figure 206 (SEQ ID NO:289), Figure 208 (SEQ ID NO:291), Figure 210 (SEQ ID NO:293), Figure 212 (SEQ ID NO:295), Figure 214 (SEQ ID NO:297), Figure 216 (SEQ ID NO:299), Figure 218 (SEQ ID NO:301), Figure 220 (SEQ ID NO:303), Figure 226 (SEQ ID NO:309), Figure 228 (SEQ ID NO:314), Figure 230 (SEQ ID NO:319), Figure 233 (SEQ ID NO:326), Figure 235 (SEQ ID NO:334), Figure 238 (SEQ ID NO:340), Figure 240 (SEQ ID NO:345), Figure 242 (SEQ ID NO:347), Figure 244 (SEQ ID NO:349), Figure 246 (SEQ ID NO:351), Figure 248 (SEQ ID NO:353), Figure 250 (SEQ ID NO:355), Figure 252 (SEQ ID NO:357), Figure

254 (SEQ ID NO:359), Figure 256 (SEQ ID NO:361), Figure 258 (SEQ ID NO:363), Figure 260 (SEQ ID NO:365), Figure 262 (SEQ ID NO:367), Figure 264 (SEQ ID NO:369), Figure 266 (SEQ ID NO:371), Figure 268 (SEQ ID NO:373), Figure 270 (SEQ ID NO:375), Figure 272 (SEQ ID NO:377), Figure 274 (SEQ ID NO:379), Figure 276 (SEQ ID NO:381), Figure 278 (SEQ ID NO:387), Figure 280 (SEQ ID NO:389), Figure 282 (SEQ ID NO:394), Figure 284 (SEQ ID NO:399), Figure 286 (SEQ ID NO:401), Figure 288 (SEQ ID NO:403), Figure 290 (SEQ ID NO:408), Figure 292 (SEQ ID NO:410), Figure 294 (SEQ ID NO:412), Figure 296 (SEQ ID NO:414), Figure 298 (SEQ ID NO:416), Figure 300 (SEQ ID NO:418), Figure 302 (SEQ ID NO:420), Figure 304 (SEQ ID NO:422), Figure 306 (SEQ ID NO:424), Figure 308 (SEQ ID NO:495), Figure 310 (SEQ ID NO:497), Figure 312 (SEQ ID NO:499), Figure 314 (SEQ ID NO:501), Figure 316 (SEQ ID NO:503), Figure 318 (SEQ ID NO:505), Figure 320 (SEQ ID NO:507), Figure 322 (SEQ ID NO:509), Figure 324 (SEQ ID NO:511), Figure 326 (SEQ ID NO:513), Figure 328 (SEQ ID NO:515) or Figure 330 (SEQ ID NO:517), lacking its associated signal peptide.

29. A method of detecting a PRO943 polypeptide in a sample suspected of containing a PRO943 polypeptide, said method comprising contacting said sample with a PRO183, PRO184 or PRO185 polypeptide and determining the formation of a PRO943/PRO183, PRO184 or PRO185 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO943 polypeptide in said sample.

30. The method according to Claim 29, wherein said sample comprises cells suspected of expressing said PRO943 polypeptide.

31. The method according to Claim 29, wherein said PRO183, PRO184 or PRO185 polypeptide is labeled with a detectable label.

32. The method according to Claim 29, wherein said PRO183, PRO184 or PRO185 polypeptide is attached to a solid support.

33. A method of detecting a PRO183, PRO184 or PRO185 polypeptide in a sample suspected of containing a PRO183, PRO184 or PRO185 polypeptide, said method comprising contacting said sample with a PRO943 polypeptide and determining the formation of a PRO943/PRO183, PRO184 or PRO185 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO183, PRO184 or PRO185 polypeptide in said sample.

34. The method according to Claim 33, wherein said sample comprises cells suspected of expressing said PRO183, PRO184 or PRO185 polypeptide.



35. The method according to Claim 33, wherein said PRO943 polypeptide is labeled with a detectable label.

36. The method according to Claim 33, wherein said PRO943 polypeptide is attached to a solid support.

37. A method of detecting a PRO331 polypeptide in a sample suspected of containing a PRO331 polypeptide, said method comprising contacting said sample with a PRO1133 polypeptide and determining the formation of a PRO331/PRO1133 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO331 polypeptide in said sample.

38. The method according to Claim 37, wherein said sample comprises cells suspected of expressing said PRO331 polypeptide.

39. The method according to Claim 37, wherein said PRO1133 polypeptide is labeled with a detectable label.

40. The method according to Claim 37, wherein said PRO1133 polypeptide is attached to a solid support.

41. A method of detecting a PRO1133 polypeptide in a sample suspected of containing a PRO1133 polypeptide, said method comprising contacting said sample with a PRO331 polypeptide and determining the formation of a PRO331/PRO1133 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1133 polypeptide in said sample.

42. The method according to Claim 41, wherein said sample comprises cells suspected of expressing said PRO1133 polypeptide.

43. The method according to Claim 41, wherein said PRO331 polypeptide is labeled with a detectable label.

44. The method according to Claim 41, wherein said PRO331 polypeptide is attached to a solid support.

45. A method of detecting a PRO363 or PRO5723 polypeptide in a sample suspected of containing a PRO363 or PRO5723 polypeptide, said method comprising contacting said sample with a PRO1387 polypeptide and determining the formation of a PRO363 or PRO5723/PRO1387 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO363

or PRO5723 polypeptide in said sample.

46. The method according to Claim 45, wherein said sample comprises cells suspected of expressing said PRO363 or PRO5723 polypeptide.

5 47. The method according to Claim 45, wherein said PRO1387 polypeptide is labeled with a detectable label.

48. The method according to Claim 45, wherein said PRO1387 polypeptide is attached to a solid support.

10 49. A method of detecting a PRO1387 polypeptide in a sample suspected of containing a PRO1387 polypeptide, said method comprising contacting said sample with a PRO363 or PRO5723 polypeptide and determining the formation of a PRO363 or PRO5723/PRO1387 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1387 polypeptide in said sample.

15 50. The method according to Claim 49, wherein said sample comprises cells suspected of expressing said PRO1387 polypeptide.

20 51. The method according to Claim 49, wherein said PRO363 or PRO5723 polypeptide is labeled with a detectable label.

52. The method according to Claim 49, wherein said PRO363 or PRO5723 polypeptide is attached to a solid support.

25 53. A method of detecting a PRO1114 polypeptide in a sample suspected of containing a PRO1114 polypeptide, said method comprising contacting said sample with a PRO3301 or PRO9940 polypeptide and determining the formation of a PRO1114/PRO3301 or PRO9940 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1114 polypeptide in said sample.

30 54. The method according to Claim 53, wherein said sample comprises cells suspected of expressing said PRO1114 polypeptide.

35 55. The method according to Claim 53, wherein said PRO3301 or PRO9940 polypeptide is labeled with a detectable label.

56. The method according to Claim 53, wherein said PRO3301 or PRO9940 polypeptide is attached to a solid support.

57. A method of detecting a PRO3301 or PRO9940 polypeptide in a sample suspected of containing a PRO3301 or PRO9940 polypeptide, said method comprising contacting said sample with a PRO1114 polypeptide and determining the formation of a PRO3301 or PRO9940/PRO1114 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO3301 or PRO9940 polypeptide in said sample.

58. The method according to Claim 57, wherein said sample comprises cells suspected of expressing said PRO3301 or PRO9940 polypeptide.

59. The method according to Claim 57, wherein said PRO1114 polypeptide is labeled with a detectable label.

60. The method according to Claim 57, wherein said PRO1114 polypeptide is attached to a solid support.

61. A method of detecting a PRO1181 polypeptide in a sample suspected of containing a PRO1181 polypeptide, said method comprising contacting said sample with a PRO7170, PRO361 or PRO846 polypeptide and determining the formation of a PRO1181/PRO7170, PRO361 or PRO846 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1181 polypeptide in said sample.

62. The method according to Claim 61, wherein said sample comprises cells suspected of expressing said PRO1181 polypeptide.

63. The method according to Claim 61, wherein said PRO7170, PRO361 or PRO846 polypeptide is labeled with a detectable label.

64. The method according to Claim 61, wherein said PRO7170, PRO361 or PRO846 polypeptide is attached to a solid support.

65. A method of detecting a PRO7170, PRO361 or PRO846 polypeptide in a sample suspected of containing a PRO7170, PRO361 or PRO846 polypeptide, said method comprising contacting said sample with a PRO1181 polypeptide and determining the formation of a PRO1181/PRO7170, PRO361 or PRO846 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO7170, PRO361 or PRO846 polypeptide in said sample.

66. The method according to Claim 65, wherein said sample comprises cells suspected of expressing said PRO7170, PRO361 or PRO846 polypeptide.

67. The method according to Claim 65, wherein said PRO1181 polypeptide is labeled with a detectable label.

68. The method according to Claim 65, wherein said PRO1181 polypeptide is attached to a solid support.

69. A method of linking a bioactive molecule to a cell expressing a PRO943 polypeptide, said method comprising contacting said cell with a PRO183, PRO184 or PRO185 polypeptide that is bound to said bioactive molecule and allowing said PRO943 and PRO183, PRO184 or PRO185 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

70. The method according to Claim 69, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

71. The method according to Claim 69, wherein said bioactive molecule causes the death of said cell.

72. A method of linking a bioactive molecule to a cell expressing a PRO183, PRO184 or PRO185 polypeptide, said method comprising contacting said cell with a PRO943 polypeptide that is bound to said bioactive molecule and allowing said PRO943 and PRO183, PRO184 or PRO185 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

73. The method according to Claim 72, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

74. The method according to Claim 73, wherein said bioactive molecule causes the death of said cell.

75. A method of linking a bioactive molecule to a cell expressing a PRO331 polypeptide, said method comprising contacting said cell with a PRO1133 polypeptide that is bound to said bioactive molecule and allowing said PRO331 and PRO1133 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

76. The method according to Claim 75, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

77. The method according to Claim 75, wherein said bioactive molecule causes the death of said cell.

78. A method of linking a bioactive molecule to a cell expressing a PRO1133 polypeptide, said method comprising contacting said cell with a PRO331 polypeptide that is bound to said bioactive molecule and allowing said PRO331 and PRO1133 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

79. The method according to Claim 78, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

80. The method according to Claim 78, wherein said bioactive molecule causes the death of said cell.

81. A method of linking a bioactive molecule to a cell expressing a PRO1387 polypeptide, said method comprising contacting said cell with a PRO363 or PRO5723 polypeptide that is bound to said bioactive molecule and allowing said PRO1387 and PRO363 or PRO5723 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

82. The method according to Claim 81, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

83. The method according to Claim 81, wherein said bioactive molecule causes the death of said cell.

84. A method of linking a bioactive molecule to a cell expressing a PRO363 or PRO5723 polypeptide, said method comprising contacting said cell with a PRO1387 polypeptide that is bound to said bioactive molecule and allowing said PRO1387 and PRO363 or PRO5723 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

85. The method according to Claim 84, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

86. The method according to Claim 84, wherein said bioactive molecule causes the death of said cell.

87. A method of linking a bioactive molecule to a cell expressing a PRO1114 polypeptide, said method comprising contacting said cell with a PRO3301 or PRO9940 polypeptide that is bound to said bioactive molecule and allowing said PRO1114 and PRO3301 or PRO9940 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

5 88. The method according to Claim 87, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

89. The method according to Claim 87, wherein said bioactive molecule causes the death of said cell.

10 90. A method of linking a bioactive molecule to a cell expressing a PRO3301 or PRO9940 polypeptide, said method comprising contacting said cell with a PRO1114 polypeptide that is bound to said bioactive molecule and allowing said PRO1114 and PRO3301 or PRO9940 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

15 91. The method according to Claim 90, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

20 92. The method according to Claim 90, wherein said bioactive molecule causes the death of said cell.

25 93. A method of linking a bioactive molecule to a cell expressing a PRO1181 polypeptide, said method comprising contacting said cell with a PRO7170, PRO361 or PRO846 polypeptide that is bound to said bioactive molecule and allowing said PRO1181 and PRO7170, PRO361 or PRO846 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

94. The method according to Claim 93, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

30 95. The method according to Claim 93, wherein said bioactive molecule causes the death of said cell.

35 96. A method of linking a bioactive molecule to a cell expressing a PRO7170, PRO361 or PRO846 polypeptide, said method comprising contacting said cell with a PRO1181 polypeptide that is bound to said bioactive molecule and allowing said PRO1181 and PRO7170, PRO361 or PRO846 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

97. The method according to Claim 96, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

98. The method according to Claim 96, wherein said bioactive molecule causes the death of said cell.

99. A method of modulating at least one biological activity of a cell expressing a PRO943 polypeptide, said method comprising contacting said cell with a PRO183, PRO184 or PRO185 polypeptide or an anti-PRO943 antibody, whereby said PRO183, PRO184 or PRO185 polypeptide or said anti-PRO943 antibody binds to said PRO943 polypeptide, thereby modulating at least one biological activity of said cell.

100. The method according to Claim 99, wherein said cell is killed.

101. A method of modulating at least one biological activity of a cell expressing a PRO183, PRO184 or PRO185 polypeptide, said method comprising contacting said cell with a PRO943 polypeptide or an anti-PRO183, anti-PRO184 or anti-PRO185 antibody, whereby said PRO943 polypeptide or said anti-PRO183, anti-PRO184 or anti-PRO185 antibody binds to said PRO183, PRO184 or PRO185 polypeptide, thereby modulating at least one biological activity of said cell.

102. The method according to Claim 101, wherein said cell is killed.

103. A method of modulating at least one biological activity of a cell expressing a PRO331 polypeptide, said method comprising contacting said cell with a PRO1133 polypeptide or an anti-PRO331 antibody, whereby said PRO1133 polypeptide or said anti-PRO331 antibody binds to said PRO331 polypeptide, thereby modulating at least one biological activity of said cell.

104. The method according to Claim 103, wherein said cell is killed.

105. A method of modulating at least one biological activity of a cell expressing a PRO1133 polypeptide, said method comprising contacting said cell with a PRO331 polypeptide or an anti-PRO1133 antibody, whereby said PRO331 polypeptide or said anti-PRO1133 antibody binds to said PRO1133 polypeptide, thereby modulating at least one biological activity of said cell.

106. The method according to Claim 105, wherein said cell is killed.

107. A method of modulating at least one biological activity of a cell expressing a PRO1387 polypeptide, said method comprising contacting said cell with a PRO363 or PRO5723 polypeptide or an anti-PRO1387 antibody, whereby said PRO363 or PRO5723 polypeptide or said anti-PRO1387 antibody binds to said PRO1387 polypeptide, thereby modulating at least one biological activity of said cell.

108. The method according to Claim 107, wherein said cell is killed.

109. A method of modulating at least one biological activity of a cell expressing a PRO363 or PRO5723 polypeptide, said method comprising contacting said cell with a PRO1387 polypeptide or an anti-PRO363 or anti-PRO5723 antibody, whereby said PRO1387 polypeptide or said anti-PRO363 or anti-PRO5723 antibody binds to said PRO363 or PRO5723 polypeptide, thereby modulating at least one biological activity of said cell.

110. The method according to Claim 109, wherein said cell is killed.

111. A method of modulating at least one biological activity of a cell expressing a PRO1114 polypeptide, said method comprising contacting said cell with a PRO3301 or PRO9940 polypeptide or an anti-PRO1114 antibody, whereby said PRO3301 or PRO9940 polypeptide or said anti-PRO1114 antibody binds to said PRO1114 polypeptide, thereby modulating at least one biological activity of said cell.

112. The method according to Claim 111, wherein said cell is killed.

113. A method of modulating at least one biological activity of a cell expressing a PRO3301 or PRO9940 polypeptide, said method comprising contacting said cell with a PRO1114 polypeptide or an anti-PRO3301 or anti-PRO9940 antibody, whereby said PRO1114 polypeptide or said anti-PRO3301 or anti-PRO9940 antibody binds to said PRO3301 or PRO9940 polypeptide, thereby modulating at least one biological activity of said cell.

114. The method according to Claim 113, wherein said cell is killed.

115. A method of modulating at least one biological activity of a cell expressing a PRO1181 polypeptide, said method comprising contacting said cell with a PRO7170, PRO361 or PRO846 polypeptide or an anti-PRO1181 antibody, whereby said PRO7170, PRO361 or PRO846 polypeptide or said anti-PRO1181 antibody binds to said PRO1181 polypeptide, thereby modulating at least one biological activity of said cell.

116. The method according to Claim 115, wherein said cell is killed.



117. A method of modulating at least one biological activity of a cell expressing a PRO7170, PRO361 or PRO846 polypeptide, said method comprising contacting said cell with a PRO1181 polypeptide or an anti-PRO7170, anti-PRO361 or anti-PRO846 antibody, whereby said PRO1181 polypeptide or said anti-PRO7170, anti-PRO361 or anti-PRO846 antibody binds to said PRO7170, PRO361 or PRO846 polypeptide, thereby modulating at least one biological activity of said cell.

5

118. The method according to Claim 117, wherein said cell is killed.

591